Aeterna Zentaris Inc. (AEZS) Shares Down 6.6%
Aeterna Zentaris Inc. (NASDAQ:AEZS)’s share price dropped 6.6% on Tuesday . The company traded as low as $3.36 and last traded at $3.37, with a volume of 270,204 shares traded. The stock had previously closed at $3.61.
AEZS has been the subject of a number of recent analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Aeterna Zentaris in a research note on Tuesday. Canaccord Genuity reaffirmed a “buy” rating and issued a $9.00 price objective (down previously from $13.00) on shares of Aeterna Zentaris in a research note on Monday, April 4th.
The firm has a 50-day moving average price of $3.44 and a 200-day moving average price of $3.54. The firm’s market capitalization is $33.89 million.
Aeterna Zentaris Inc is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development.